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Background: Intrapartum administration of single-dose nevirapine (sdNVP) reduces perinatal HIV-1 transmission in
resource-limiting settings by half. Yet this strategy has limited effect on subsequent breast milk transmission,
making the case for new treatment approaches to extend maternal/infant antiretroviral prophylaxis through the
period of lactation. Maternal and transmitted infant HIV-1 variants frequently develop NVP resistance mutations
following sdNVP, complicating subsequent treatment/prophylaxis regimens. However, it is not clear whether
NVP-resistant viruses are transmitted via breastfeeding or arise de novo in the infant.
Findings: We performed a detailed HIV genetic analysis using single genome sequencing to identify the origin of
drug-resistant variants in an sdNVP-treated postnatally-transmitting mother-infant pair. Phylogenetic analysis of HIV
sequences from the child revealed low-diversity variants indicating infection by a subtype C single transmitted/
founder virus that shared full-length sequence identity with a clonally-amplified maternal breast milk virus variant
harboring the K103N NVP resistance mutation.
Conclusion: In this mother/child pair, clonal amplification of maternal NVP-resistant HIV variants present in systemic
and mammary gland compartments following intrapartum sdNVP represents one source of transmitted NVP-resistant
variants that is responsible for the acquisition of drug resistant virus by the breastfeeding infant. This finding
emphasizes the need for combination antiretroviral prophylaxis to prevent mother-to-child HIV transmission.
Keywords: Mother-to-child transmission, Breast milk, HIV-transmission, Nevirapine, Drug-resistant variant, K103N,
Transmitted virus, Clonal amplification, Antiretroviral prophylaxisIntroduction
In 2011, 330,000 infants acquired HIV infection from
their mothers [1]. Most of mother-to-child transmissions
(MTCT) occur in low- and middle-income countries,
where HIV transmission through breastfeeding accounts
for 30–50% of infant infections in the absence of anti-
retroviral (ARV) prophylaxis [2]. In sub-Saharan Africa,
formula feeding is not a recommended alternative due
to its association with increased morbidity and mortality,* Correspondence: salazarj@uab.edu
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reproduction in any medium, provided the orcaused by malnutrition, respiratory diseases and diar-
rheal complications [3]. Furthermore, several studies
have substantiated the benefit of breastfeeding over
formula feeding, despite the risk of breast milk trans-
mission [4-6]. WHO currently recommends exclusive
breastfeeding for the first 6 months of life, followed by
complementary foods and breastfeeding until 12 months
of age, accompanied by postnatal infant or maternal anti-
retroviral prophylaxis to reduce HIV transmission during
breastfeeding [1]. Initial studies showed that intrapartum
single-dose nevirapine (sdNVP) prophylaxis reduced the
risk of MTCT by half [7] but lacked efficacy to prevent
breast milk HIV transmission. More recently, extendedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion when compared to sdNVP [8]. Though convenient,
inexpensive, and effective, sdNVP prophylaxis selects for
NVP-resistant (NVP-R) variants in a high proportion of
women (19–75%) and their infected infants (33–87%)
[9,10] and these variants remain detectable for a year or
more [10-12]. Moreover, NVP-R variants emerge more
frequently and persist longer after exposure to extended
NVP prophylaxis [13,14], while sdNVP administration in-
creases the risk of virologic failure to subsequent ARV
treatment [15].
Although a large fraction of infants harbor NVP-R var-
iants following perinatal NVP administration, it is not
clear whether NVP-R variants are transmitted to the in-
fant postnatally or if they arise de novo in the infant
[9-11,16]. Previous studies have not rigorously examined
the drug-resistant profile of transmitted/founder (T/F)
virus (es) that are responsible for transmission and pro-
ductive clinical infection in the infant [10,11,13,14,16].
Understanding the precise origin of drug-resistant strains
in MTCT may aide in the design of improved, more
broadly effective prophylaxis regimens that will not impair
future treatment options for infected infants. Our previous
study of chronically HIV-infected Malawian lactating
women who received intrapartum sdNVP revealed contin-
ual trafficking of blood-derived viral variants into the
mammary glands followed by transient local replication of
some variants that disproportionally contributed to low-
diversity (clonally-amplified) viral populations in breast
milk [17]. Here we hypothesized that clonally-amplified
variants in breast milk are selected for drug-resistance by
NVP and that they are likely to be transmitted to the in-
fant due to their proportional abundance and selective
replication fitness in the presence of NVP. To test this
hypothesis, we conducted a longitudinal genetic and drug-
resistant mutation analysis of HIV variants in plasma and
milk of a postnatal-transmitting mother-infant pair follow-
ing sdNVP administration.
Findings
Postnatal transmission of a single virus and time
estimates of infection by HIV sequence diversity analysis
in the infant
We studied a chronically subtype C HIV-infected lactat-
ing Malawian woman (subject 4403) who received
intrapartum sdNVP prophylaxis (200 mg) to prevent
MTCT the day before delivery, gave birth to an unin-
fected child and was followed longitudinally for 12 weeks
(Table 1, Additional file 1). The child, subject 4419, re-
ceived a NVP dose at birth (2 mg NVP/Kg of weight),
tested blood HIV DNA PCR negative at birth and four
weeks of age and continued to be breastfed by the mother
until 6 months of age. At 12 weeks of age, the child had a
positive blood HIV DNA PCR, and high plasma viral load(1,210,000 copies/ml) strongly supporting breast milk
transmission with the two previous negative tests. Under
these circumstances, a potentially transmitted NVP-R
virus may have a fitness advantage over wild-type virus
with NVP-R variant being able to establish productive in-
fection in the setting of the long life of NVP. The infant
subsequently died at 6 months of age of respiratory compli-
cations, despite trimethoprim-sulfamethoxazole prophy-
laxis. Phylogenetic analysis of multiple envelope (env)
sequences derived from child’s plasma at the time of HIV
diagnosis (Additional file 1) revealed low-diversity se-
quences (mean nucleotide diversity: 0.10%, range: 0.00–
0.20%) suggesting recent infection by a single virus.
Indeed, env sequences conformed to predictions of a
mathematical model of random evolution by a single virus
[18]; as sequences exhibited a Poisson distribution of mu-
tations and star-like phylogeny, which coalesced to an in-
ferred consensus sequence that identifies the virus present
at or near the estimated time of transmission (Table 2).
Using Poisson model parameters, the mean env diver-
gence time of the 12-week sample (83 days postpartum)
since a most recent common ancestor (MRCA) was
43 days (95% confidence intervals [CI]: 32, 54 days), a time
consistent with postpartum transmission of a single virus.
In addition, when sets of 5’-half and 3’-half infant HIV ge-
nomes were analyzed, each set conformed to model pre-
dictions, as described above for env-only sequences
(Table 2). Moreover, time interval estimates since the
MRCA overlapped in all three data sets and fell within the
time frame of the last HIV PCR negative (4 weeks of age)
and first PCR positive test (12 weeks of age) of the infant.
Given the relative immaturity of the infant’s immune sys-
tem during the first few months of life, the low sequence
diversity and Poisson distribution of mutations in the viral
quasispecies support negligible effect of immune selection
pressure of placentally-acquired maternal antibodies. Under
conditions of low-selection pressure, time estimates since a
MRCA for the infected child using the Poisson model are
reliable and comparable to those estimated by Bayesian
methods [18]. Accordingly, a Bayesian relaxed clock-based
analysis of env sequences (Additional file 1) estimated a
mean of 54 days (95% highest probability density intervals:
17, 105) since a MRCA, which is slightly higher than the
Poisson estimate but consistent with predictions based on
the infant HIV-1 testing. Together, these data suggest that
the child could have been infected as early as 4.3 weeks or
as late as 7.7 weeks of age.
The inferred infant T/F HIV genome is closely related to a
population of low-diversity variants in maternal breast
milk near the predicted time of infection
A maximum-likelihood tree clearly showed that the
child’s env sequences (indicated with a vertical orange
bar in Figure 1A) cluster together with a group of low-
Table 1 Clinical and virological data of chronically HIV-infected lactating woman 4403
Sample ID weeks
postpartum
Sample date Plasma virus
load (copies/ml)
Breast milk virus load,
left and right (copies/ml)
CD4 count
(cells/μl)
ART* prophylaxis Infant blood HIV
DNA PCR status
Third trimester of pregnancy 04/25/08 519,000 208
Parturition 05/24/08 56,200 Maternal sdNVP
on 05/23/08
PCR negative
Week 4 06/27/08 100,892 Left: 101,500 PCR negative
Right: 30,450
Week 12 08/15/08 2,120 Left: <240 PCR positive
* ART denotes antiretroviral therapy.
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Figure 1A) present among a genetically heterogeneous
virus population derived from breast (left and right) milk
collected at 4 weeks postpartum. A similar pattern was
observed when we analyzed viral pol sequences from
mother and child (Figure 1B). The clustering of child
and maternal sequences in a single branch of identity
and near-identity (using two different HIV genes) re-
vealed the anatomical source of the transmitted virus,
and its exact genetic identity. Next, we inferred the full-
length nucleotide sequence of the virus that established
infection in the child. A highlighter plot of partially
overlapping 5’- and 3’-half genomes derived from plasma
at diagnosis (12 week of age) show few random muta-
tions with sequences coalescing to a single consensus
that represents the T/F virus (Figure 2A). Two se-
quences in each half genome were identical to the infant
consensus virus, while most other sequences were 1, 2,
or 3 nucleotides away from the consensus. A subset of
viruses exhibited shared polymorphisms not found in
maternal sequences that are interpreted as stochastic
mutations occurring in the early replication cycles of the
founder virus, but with enough fitness to persist as mi-
nority variants. Figure 2B show maternal low-diversity
HIV (pol and rev/env) sequences from 4 weeks postpar-
tum breast milk (right and left breast for env sequences)
coalescing to a consensus identical to the infant consen-
sus virus, thus suggesting common ancestry. Most milk
sequences differed from consensus by 0, 1, 2, and 3 nu-
cleotides, while sequences with >4 nucleotide changes
represented viral recombinants with more divergent
virus sequences (mutations clustered within a restrictedTable 2 Statistics and mathematical model timing estimates o
















Env-only 22 2571 7 2.6 43 (3
3’-half 22 4682 10 4.3 38 (3
5’-half 21 5349 9 4.7 37 (3region of the genome and were present in other phylo-
genetically distant milk sequences). Clonally-amplified
pol and rev/env milk sequences were linked by an ampli-
fied 9 Kb milk variant (Figure 2B, sequence below the
consensus) that differed from the infant full-length T/F
virus by only two nucleotides, indicating common ances-
try. Recombination of clonally-amplified milk variants
with more divergent viral sequences was substantial;
examples of recombination spots are indicated within a
circle for three milk sequences including a second 9 Kb
amplicon (Figure 2B, bottom sequence). The infant
virus and the corresponding clonally-amplified maternal
breast milk variant had intact open reading frames for
all nine major protein-coding HIV genes, as expected
and shown previously for all T/F virus genomes [19].
Together, these data confirm that the mammary gland is
the anatomical source of the postnatally-transmitted
virus.
The transmitted virus is a NVP-R variant that underwent
prior selection and clonal amplification in the
lactating mother
Because sdNVP prophylaxis is known to select for NVP-R
variants [9-11], we investigated drug resistance mutations
in the milk and infant virus sequences. We observed that
the K103N mutation which confers high-level resistance
to NVP [20] was present in all of the infant’s pol gene se-
quences, and hence the T/F virus (marked with an arrow
in Figure 2A), as well as in 50% of maternal plasma and
80% of breast milk pol sequences (Figure 3). Without ex-
ception, pol sequences from the major clonally-amplified
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Figure 1 Maximum-likelihood trees of env and pol genes from 4403–4419 MTCT pair. Maternal breast milk virus env (A) and pol (B) sequences
(blue stars = right breast; blue circles = left breast) were obtained from a sample collected at 4 weeks postpartum and infant virus env (A) and pol
(B) sequences (orange squares) were derived from a plasma sample collected at 12 weeks of age. Groups of identical/near-identical sequences
(defined as sequences with four or fewer nucleotide substitutions compared to consensus sequence) in maternal breast milk (vertical blue bar) or
infant plasma (vertical orange bar) are indicated. Greater than 90% of the indicated near-identical sequences had fewer than four substitutions
compared to consensus. Numerals at nodes indicate approximate bootstrap support values≥ 70%. The scale bar represents 0.001 (0.1%) nucleotide
substitutions per site.
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(Figures 2B and 3). Identifying the mechanisms under-
lying HIV clonal amplifications in breast milk may have
important implications in transmission risk and guiding
the development of new prophylactic strategies. Major
clonally-amplified env variants accounted for 35% and
50% of the total breast milk virus population at four weeks
postpartum from right (13/37 sequences) and left breast
(22/44 sequences), respectively (Figure 1A). Clonally-
amplified variants were also present in maternal plasma at
4 weeks postpartum (Figure 4), albeit with slightly lower
frequency to that seen in breast milk (29%; 11 out of 38
env sequences) as previously shown [17]. Although the
K103N mutation was not present in any of 9 SGA and 12
end-point PCR-amplified plasma sequences at 3rd trimes-
ter of gestation, one out of eight pol sequences derived
from maternal plasma collected after delivery (approxi-
mately one day after sdNVP) had the K103N mutation
(clone pE7). The one-log reduction in plasma viral load
that occurred between the 3rd trimester and parturition
samples (519,000 vs. 56,200 copies/ml, respectively) wasan indication of the antiretroviral response between NPV
administration at the onset of labor and sample collection
one day later. Although the depth of sequencing was not
sufficient to determine whether clone pE7 which was
present at parturition preexisted as a low-frequency vari-
ant before NVP prophylaxis, mathematical models [21]
and a pooled analysis of several clinical studies [22] sug-
gest that virologic failure is most likely caused by the pre-
existence of low-frequency resistant mutants. Four weeks
after delivery, wild-type NVP-R susceptible virus was nearly
replaced with variants carrying individual non-nucleoside
reverse transcriptase inhibitor (NNRTI)-resistance muta-
tions such as K103N, V106M, Y188L and G190A, and
importantly, the generation of a major clonally-amplified
variant carrying K103N mutation in the mammary gland
compartment (Figure 3). Thus, our data are in line with the
likelihood that NVP-R variants preexisted prior to sdNVP
prophylaxis in subject 4403. Together, these data identified
i) the maternal breast milk as the source of the postnatally-
transmitted NVP-R virus, and ii) NVP selection pressure
as the underlying mechanism for the clonal amplification
Figure 2 (See legend on next page.)
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Figure 2 Highlighter analyses of HIV sequences from infant plasma and maternal breast milk. (A) Multiple 5’-half and 3’-half genome
sequences derived from infant plasma at the time of HIV diagnosis are aligned below the infant consensus sequence (Con). Nucleotide
differences from the inferred T/F consensus sequence are indicated by tic marks color-coded for each base. IUPAC denotes International Union of
Pure and Applied Chemistry ambiguous base assignments caused by Taq polymerase-induced nucleotide misincorporation occurring in the first
two cycles of the PCR amplification. Flanking gray boxes indicate regions not amplified. Gray tics indicate deletions. The arrow indicates the
location of the K103N mutation in the RT gene in consensus and all SGA sequences (AAA to AAC mutation). The horizontal axis indicates
nucleotide positions based on HXB2 reference sequence numbering. Consensus sequence begins at nucleotide position 484 in the 5’ long
terminal repeat (LTR) U5 and extend to position 9,606 in the 3’ LTR R. (B) Two 9 Kb amplicons, and multiple pol and rev/env fragments
representing low-diversity breast milk sequences collected at four weeks postpartum (shown at the left of the blue bars in Figure 1) are aligned
below the consensus sequence (identical to Con from Figure 1A). The arrow represents the location of the K103N mutation. Clustered mutations
enclosed in elipses reflect recombination with more divergent maternal sequences. The horizontal axis indicates HXB2 nucleotide positions.
Sequences begin at nucleotide position 582 in the 5’ LTR U5 and extend to position 9,606 in the 3’ LTR R. Boxes corresponding to LTRs and 9
major protein coding regions of the HIV genome are shown at the bottom.
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subsequent transmission. Finally, the complete replace-
ment of wild-type virus with NNRTI-resistant mutants
was evident by 12 weeks postpartum coupled with a sig-
nificant reduction of viral load in plasma and breast milk
(Table 1); K103N mutation was present in 5 out of 8
(63%) pol sequences, whereas NNRTI resistance muta-
tions V106M, Y188C or G190A were each present in 3
other sequences (Figure 3). Moreover, maternal week 12
viral variants were genetically heterogeneous and phylo-
genetically distinct from week 4 clonally-amplified vari-
ants; new clusters of near-identical env sequences (shown
inside circles in Figure 4), indicated ongoing evolution
and the transient nature of clonally-amplified variants as
previously observed [17].
Discussion and conclusions
Few studies have addressed the origin of NVP-R variants
observed in postnatally-infected infants. Studies propos-
ing transmission of NVP-R variants in infants based
their conclusion on the results of a first time HIV posi-
tive test done at late times during the breastfeeding
period under the assumption that NVP had been cleared
from tissues [13,14]. Yet, the time interval between the
infant HIV testing is usually broad in these studies, and
the existing analyses did not include a time estimate
since a MRCA of the variants using sequence diversity.
Studies that have proposed transmission of wild-type
virus followed by selection of resistant variants that were
only detectable by sensitive assays based their interpret-
ation on the timing of infection and likely exposure to
NVP [10,11,23]. A similar interpretation should follow
when population sequencing shows mixed wild-type and
resistant viruses, unless both forms were simultaneously
transmitted; a scenario less likely given the genetic
bottleneck of MTCT of HIV [24,25] and the fact that
most (~80%) HIV infections in heterosexuals [18,26] and
infants via breast milk [27] result from transmission of a
single virus. Thus, our study is important in that itestablishes the NVP-R breast milk virus population se-
lected by maternal sdNVP as the origin of the NVP-R
virus in this postnatally-infected infant. However, our
experimental design has a number of limitations. For
instance, we cannot exclude the possibility that infection
resulted from transmission of multiple identical viral
genomes such as the progeny from a single infected cell
in maternal milk, yet this limitation does not change
our conclusion that the infant was infected by a NVP-R
virus strain. Also, although we cannot exclude that the
infecting virus strain in the infant could have been trans-
mitted perinatally, our strict definition for breast milk
transmission, i.e., HIV DNA PCR negative at birth and
4–6 weeks, but PCR positive at 12 weeks or later falls
within the most likelihood for most cases of postnatal
HIV transmission. However, these limitations do not im-
pact the focus of this study which was to clarify whether
NVP-R resistance is transmitted or arise de novo in the
newly infected child. Antiretroviral treatment of an in-
fant who harbors variants with resistance to a compo-
nent of the antiretroviral treatment is more likely to fail
therapy [28].
Breast milk HIV quasispecies include multiple inde-
pendent lineages with evidence of intermixing with
plasma virus [17,29-31], while some variants undergo
clonal bursts of replication [17,30,31]. Clusters of mono-
typic and low-diversity variants have also been reported
in blood and different body compartments such as the
female genital tract [32], lung [33], semen [34], and cere-
brospinal fluid [35]. Compartmentalization and local
replication have been proposed as an explanation. Here,
we propose that upon selection by NVP, blood NVP-R
variants traffic into the mammary gland and seed the
breast milk compartment. Next, a single NVP-R variant
undergoes bursts of local replication, contributing a
disproportionately large number of NVP-R virions in
the milk virus pool and facilitating transmission of a
drug-resistant virus via breastfeeding. The abundance of
K103N clonal variants in the mother, and high-level
Figure 3 Selection of HIV-1 RT drug-resistance mutations following ARV drug exposure in maternal plasma samples. Amino acid
alignment of pol gene regions indicating single point mutations associated with high-level resistance to ARV drugs in subject 4403. CON denotes
amino acid consensus sequence from the earliest maternal plasma sample. Bold amino acid residues in the consensus correspond to selected
drug-resistant point mutations. Point mutations numbered 1–4 are as follows: 1 for K103N, 2 for V106M, 3 for Y188C/L, 4 for G190A. Dashes
denote identity with consensus, while letters correspond to amino acid changes. Asterisks indicate sequences derived from near end-point diluted
PCR positive wells (50% positive PCR wells). All other HIV pol sequences were derived by SGA as described [19]. bmL denotes milk sequences derived
from left breast; all other sequences are derived from blood plasma. Low-diversity clonally-amplified sequences (0–2 nucleotides away from
consensus; bmL_pG5 is a recombinant virus harboring a cluster of 6 nucleotide mismatches shared with more divergent virus sequences) are
indicated with brackets.















Figure 4 Neighbor-joining trees of maternal 4403 env
sequences from longitudinal plasmas samples. Full-length
maternal env sequences generated by SGA from third trimester
pregnancy and follow-up visits up to 12 weeks postpartum were
aligned and plotted as radial Neighbor-joining trees. Clusters of
monotypic and low-diversity sequences are encircled; the number of
nucleotides by which these sequences differ from MRCA (branch
node) is indicated for each cluster. The scale bar represents 0.01
nucleotide substitutions per site (1% divergence).
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suggest that this mutation has little impact on viral fit-
ness. Indeed, K103N mutation is one of the most com-
mon mutations selected by NVP as reported in previous
MTCT studies [11,36]. Moreover, in vitro studies indicated
that K103N mutation has no effect on replication fitness,
while the Y181C mutation results in a much less fit virus
when introduced in the backbone of the subtype C mo-
lecular clone MJ4 [37]. Our data demonstrate that a single
antiretroviral drug, such as NVP provides a mechan-
ism underlying the clonal amplification of resistant
variant(s) in breast milk, thus increasing the transmis-
sion risk of drug-resistant viruses in infants. The role
of ARV drugs in shifting the viral landscape toward
the clonal amplification of drug-resistant variants de-
serves to be further investigated.In summary, although we are reporting a single MTCT
pair analysis, our data are in line with other studies that
emphasize the need to implement MTCT prophylaxis
strategies that reduce the risk of development and clonal
amplification of drug resistant variants in maternal blood
and breast milk to prevent MTCT of drug-resistant
HIV variants. Our work suggests that administration
of sdNVP prophylaxis can lead to postnatal transmis-
sion of selected NVP-R variants, and support the global
implementation of effective multidrug maternal/infant
prophylaxis strategies to prevent infant acquisition of
drug-resistant HIV variants that will complicate pediatric
ARV treatment strategies.Additional file
Additional file 1: Material and methods.
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